Drug
Rgb 02 OR Neulasta
Rgb 02 OR Neulasta: highest development phase Phase 1, developed by Gedeon Richter. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Gedeon Richter
Trials
| Drug | Phase | Indication |
|---|---|---|
| RGB-02 or Neulasta® (pegfilgrastim) NCT03146988 | Phase 1 | Bioequivalence |
Latest
No recent events.
Follow Rgb 02 OR Neulasta on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.